Navigation Links
Abbott's Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA
Date:1/28/2008

Lopinavir/ritonavir tablet is the first and only co-formulated protease

inhibitor tablet approved for use in children with HIV

ABBOTT PARK, Ill., Jan. 28 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the European Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has issued a positive opinion recommending approval of a new, lower-strength tablet formulation of the company's leading HIV protease inhibitor, Kaletra(R) (lopinavir/ritonavir). In addition, the CHMP has adopted a positive opinion, in coordination with the World Health Organization (WHO), for Aluvia(R) (lopinavir/ritonavir), the tradename of the same lower-strength tablet formulation in developing countries.

The new lower-strength formulation is suitable for pediatric use and represents a significant breakthrough for clinicians and patients in developing countries, where more than 2 million of the estimated 2.3 million children worldwide with HIV/AIDS live. The first and only co-formulated protease inhibitor tablet that can be used in children, the tablets do not require refrigeration and can be taken with or without a meal -- an important advance in delivering HIV medicine in developing countries.

"EMEA approval is an essential first step to registering the tablet in Europe and most developing countries and it is welcome news for physicians and caregivers of children with HIV," said Mark Kline, M.D., professor of pediatrics, chief of Retrovirology, director, AIDS International Training and Research Program, and director, Baylor-CDC Global AIDS Technical Assistance Project, Baylor College of Medicine. "The development of this product, which does not require refrigeratio
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Abbott Receives U.S. Food and Drug Administration Approval for New Lower-Strength Kaletra(R) (lopinavir/ritonavir) Tablet for Pediatric HIV Patients
2. Ugandan Children Are Among the First to Receive Abbotts Lower-Strength Aluvia (lopinavir/ritonavir) Tablet
3. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Actavis Launches Carvedilol Tablets in the U.S.
6. Mylan Announces Final FDA Approval for Carvedilol Tablets
7. Ranbaxy Gains Approval to Manufacture and Market Carvedilol Tablets in the U.S. Market
8. Actavis Launches Amlodipine Tablets in the U.S.
9. Tablet is better all round for cancer patients
10. Roxane Laboratories, Inc. Announces the Launch of Oxcarbazepine Tablets, 150mg, 300mg and 600mg
11. Mylan Announces Settlement of Paroxetine Hydrochloride Extended-Release Tablets with GlaxoSmithKline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... September 18, 2014 Demand for competency-based ... seek more efficient routes to job placement and employers ... not have come at a better time as the ... supply. , Working in collaboration with employers, career educators ... approach to CBE implementation and direct assessment ...
(Date:9/18/2014)... September 18, 2014 With the ... special functions of adjusting human body physiology, preventing ... great popularity with a variety of specific populations. ... in China reached RMB187.4 billion, up 12.0% year ... 2006-2013. , View Full Report at http://www.marketresearchreports.biz/analysis/223449 ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Nucleus ... Community Support Services, serves the communities of Mississauga, ... in Toronto. Funded by Mississauga Local Health ... and Long Term Care, Nucleus embraces and has ... philosophy. , Nucleus was seeking a trusted ...
(Date:9/18/2014)... Specialty Teleradiology LLC, a provider ... that they have achieved Meaningful Use and increased ... Ambulatory EHR-certified system developed by RamSoft. , ... non MU compliant PACS and a RIS that ... a niche in oncology to other subspecialties, they ...
(Date:9/18/2014)... The Nautilus/ASG relationship is perfectly suited to ... even long term data archiving, to verticals that store ... This includes media and entertainment, life sciences and the ... and ASG-Digital Archive will drive down the cost of ... pleased to work with ASG to expand its ...
Breaking Medicine News(10 mins):Health News:Wonderlic Unites Employers, Career Educators and Competency-Based Education Experts to Help Narrow Skills Gap 2Health News:China Health Food Industry Size 2014 Market Analysis, Growth, Trends and Forecast Report 2017: MarketResearchReports.biz 2Health News:China Health Food Industry Size 2014 Market Analysis, Growth, Trends and Forecast Report 2017: MarketResearchReports.biz 3Health News:China Health Food Industry Size 2014 Market Analysis, Growth, Trends and Forecast Report 2017: MarketResearchReports.biz 4Health News:Nucleus Independent Living Enables Rapid Response to Care with CellTrak™ 2Health News:Nucleus Independent Living Enables Rapid Response to Care with CellTrak™ 3Health News:Nucleus Independent Living Enables Rapid Response to Care with CellTrak™ 4Health News:Specialty Teleradiology Attains Meaningful Use with PowerServer MU 2Health News:Specialty Teleradiology Attains Meaningful Use with PowerServer MU 3Health News:storageFOUNDRY and ASG Software Solutions Partner to Integrate ASG-Digital Archive with the Nautilus Software-Defined Storage Platform 2Health News:storageFOUNDRY and ASG Software Solutions Partner to Integrate ASG-Digital Archive with the Nautilus Software-Defined Storage Platform 3
... Attributes proprietary database and technology for its 296 ... HTH Worldwide, a global health and,safety services company, ... for Greater Philadelphia, a ranking of the 50 ... in the,area by Deloitte LLP, one of the ...
... ANN ARBOR, Mich., Oct. 31 Terumo Heart ... System (LVAS) was,implanted in October at the University ... efforts toward an early application for approval,for manufacture ... the world,s first third generation left ventricular,assist system ...
... Oct. 31 Relaxation specialists,Lifehut.com, have released their ... "Finding Joy During Challenging Financial,Times.", Aimed at ... to allow people to enter an alpha state ... much going on in our economy, job layoffs ...
... its 5,000 Percent Revenue Growth from FY03-FY07 to Increased ... ... Accuray,Incorporated (Nasdaq: ARAY ), has been named to ... companies. This year,s Silicon Valley Technology Fast 50,program is co-presented ...
... Natural health news site,NaturalNews.com has teamed with ... omega-3 supplement to health-conscious consumers. Made,from green-lipped mussel ... of,New Zealand, Moxxor is a nutrient-rich marine omega-3 ... to enhance and support the,body,s healthy response to ...
... million (+30%y/y), EPS $0.23 (+44% y/y) - ... ... YORK, Oct. 31 HMS Holdings Corp. (Nasdaq:,HMSY) today announced its financial ... For the quarter ended September 30, 2008 revenue increased 30% to $49.0,million, ...
Cached Medicine News:Health News:HTH Worldwide Ranked Number 21 in Deloitte's Fast 50 Program for Greater Philadelphia 2Health News:HTH Worldwide Ranked Number 21 in Deloitte's Fast 50 Program for Greater Philadelphia 3Health News:Lifehut.com Aims to Relax the Financially Stressed 2Health News:Accuray Incorporated Ranked Fifth in Deloitte's Technology Fast 50 Program for Silicon Valley Scientific/Medical Equipment, and Biotechnology Companies 2Health News:Accuray Incorporated Ranked Fifth in Deloitte's Technology Fast 50 Program for Silicon Valley Scientific/Medical Equipment, and Biotechnology Companies 3Health News:Accuray Incorporated Ranked Fifth in Deloitte's Technology Fast 50 Program for Silicon Valley Scientific/Medical Equipment, and Biotechnology Companies 4Health News:NaturalNews Partners with Moxxor to Bring Marine Omega-3 Supplement to Health-Conscious Consumers 2Health News:HMS Holdings Corp. Announces Q3 2008 Results, 2008 Revised Guidance and Initial 2009 Guidance 2Health News:HMS Holdings Corp. Announces Q3 2008 Results, 2008 Revised Guidance and Initial 2009 Guidance 3Health News:HMS Holdings Corp. Announces Q3 2008 Results, 2008 Revised Guidance and Initial 2009 Guidance 4Health News:HMS Holdings Corp. Announces Q3 2008 Results, 2008 Revised Guidance and Initial 2009 Guidance 5Health News:HMS Holdings Corp. Announces Q3 2008 Results, 2008 Revised Guidance and Initial 2009 Guidance 6Health News:HMS Holdings Corp. Announces Q3 2008 Results, 2008 Revised Guidance and Initial 2009 Guidance 7Health News:HMS Holdings Corp. Announces Q3 2008 Results, 2008 Revised Guidance and Initial 2009 Guidance 8Health News:HMS Holdings Corp. Announces Q3 2008 Results, 2008 Revised Guidance and Initial 2009 Guidance 9Health News:HMS Holdings Corp. Announces Q3 2008 Results, 2008 Revised Guidance and Initial 2009 Guidance 10
(Date:9/18/2014)... and CHESTERBROOK, Pa. , Sept. 18, 2014 ... ) and Auxilium Pharmaceuticals, Inc. (Nasdaq: ... Administration (FDA) has approved a supplemental new drug application (sNDA) ... FDA-approved erectile dysfunction (ED) medication indicated to be taken as ... STENDRA is a prescription medication in a class of drugs ...
(Date:9/17/2014)... Sept. 17, 2014 North America Gynecological ... GlobalData,s new report, "North America ... market data on the North America Gynecological Devices ... US dollars, volume (in units) and average prices ... Sterilization Devices (Transcervical Sterilization Devices (Micro-inserts) and Mechanical ...
(Date:9/17/2014)... NEW YORK , Sept. 17, 2014 /PRNewswire/ ... to 2020 Summary ... to 2020", provides key market data on the ... in millions of US dollars, volume (in units) ... segments - Female Sterilization Devices (Transcervical Sterilization Devices ...
Breaking Medicine Technology:VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 2VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 3VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 4VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 5VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 6VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 7VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 8VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 9North America Gynecological Devices Market Outlook to 2020 2North America Gynecological Devices Market Outlook to 2020 3Brazil Gynecological Devices Market Outlook to 2020 2Brazil Gynecological Devices Market Outlook to 2020 3
... CHICAGO, Dec. 2 New research has found that the ... an emergency room can significantly increase the number of stroke ... study, conducted at North Shore Medical Center (NSMC)-Salem Hospital in ... of the Radiological Society of North America (RSNA). , ...
... an oral,presentation of preliminary results from a multi-center, US-based clinical,trial of TG101348 in myeloproliferative disease ... Details of the presentation are as follows:, Title: ... TG101348, an Orally Bioavailable, ... ...
Cached Medicine Technology:Portable CT Increases Chance of Stroke Survival and Recovery 2Portable CT Increases Chance of Stroke Survival and Recovery 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: